Antimetabolite in the Management of Odontogenic Keratocyst-A Case Report.
5 fluorouracil
Antimetabolite
Basal cell carcinoma
Odontogenic keratocyst
Journal
Journal of maxillofacial and oral surgery
ISSN: 0972-8279
Titre abrégé: J Maxillofac Oral Surg
Pays: India
ID NLM: 101538309
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
13
03
2022
accepted:
05
06
2022
pmc-release:
01
03
2024
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
28
1
2023
Statut:
ppublish
Résumé
Odontogenic keratocyst (OKC) is an aggressive cystic lesion of the jaw with high growth and recurrence. Patients are usually asymptomatic and detected during routine radiographic examination. Management of OKC varies from conservative procedures like simple Enucleation and peripheral ostectomy to aggressive resection. More attention is given to new treatment protocols to form them simple and successful. 5 fluorouracil is an anti-metabolite used to treat basal cell carcinoma and other malignancies act by inhibiting thymidylate synthase an enzyme required for DNA synthesis causing cell death. This is a case report of a 40-year-old female patient with OKC treated with topical 5 fluorouracil after enucleation, has less morbidity minimal recurrence, and low cost.
Identifiants
pubmed: 36703675
doi: 10.1007/s12663-022-01751-0
pii: 1751
pmc: PMC9871097
doi:
Types de publication
Case Reports
Langues
eng
Pagination
132-135Informations de copyright
© The Association of Oral and Maxillofacial Surgeons of India 2022.
Références
Oral Maxillofac Surg Clin North Am. 2003 Aug;15(3):383-92
pubmed: 18088690
Dermatol Surg. 2007 Apr;33(4):433-9; discussion 440
pubmed: 17430377
Int J Oral Maxillofac Surg. 2019 Mar;48(3):415-416
pubmed: 30145063
Med Hypotheses. 2006;67(5):1242-4
pubmed: 16806729
Carcinogenesis. 2006 Nov;27(11):2286-94
pubmed: 16777989
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):404-406
pubmed: 32775182